Clinical trial NCT05971381: Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells
Official title: The TONE Study: A Prospective Post-Market Clinical Study Investigating Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vitiligo
Keywords: focal vitiligo
segmental vitiligo
nonsegmental vitiligo
generalized vitiligo
Lead sponsor: Avita Medical
Sponsor class: INDUSTRY
First posted: 2023-08-02
Enrollment: 109
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.

Detailed description: Prospective, multicenter single-arm pre-/post interventional study to evaluate the clinical performance of RECELL for repigmentation of stable depigmented lesions.Skin cell suspension prepared using the RECELL System will be applied to a prepared treatment area, followed by at-home NB-UVB phototherapy.

Repigmentation of treatment areas will be determined via centralized image interpretation by an expert dermatological panel (i.e., Central Review Committee, CRC).

Eligibility criteria: Inclusion Criteria:

1. Focal, segmental, or generalized (i.e., nonsegmental) stable vitiligo, defined as no new depigmented areas nor any depigmented areas that have expanded in size within the preceding 12 months.
2. The patient is a candidate for surgical intervention of a depigmented area, defined as a patient who has not satisfactorily responded to either:

   1. topical therapy or
   2. a minimum of 3 months of phototherapy.
3. The patient has a depigmented area available for treatment that is:

   1. ≥90% depigmented,
   2. without any other dermatologic conditions (other than vitiligo), and
   3. excludes the lips, eyelids, plantar surface of feet, palmar surface of hands.
4. The patient is 18 years of age or older.
5. The patient agrees to remain on any current use of immunosuppressive therapy for the duration of his/her participation in the study (52 weeks).
6. The patient is willing and able to comply with post-treatment at-home phototherapy and all follow-up study visits.
7. The patient agrees to abstain from any other treatment of the study area for the duration of his/her participation in the study (52 weeks).
8. The patient agrees to abstain from enrollment in any other interventional clinical trial for the duration of his/her participation in the study (52 weeks).
9. In the opinion of the investigator, the patient must be able to:

   1. Understand the full nature and purpose of the study, including possible risks and benefits,
   2. Understand instructions and be able to comprehend and complete study questionnaires, and
   3. Provide voluntary written informed consent. -

Exclusion Criteria:

1. The patient is unable to undergo treatment area preparation.
2. Patients who received RECELL treatment for vitiligo in Protocol No. CTP008 or CTP009.
3. Patients with:

   1. depigmented lips and fingertips (lip-tip vitiligo), or
   2. depigmented areas over \>30% of their body surface area.
4. Patients with recent history (within previous 12 months) of:

   1. Koebnerization,
   2. confetti-like, or
   3. trichrome lesions.
5. Patients with a history of keloid formation.
6. The patient has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives.
7. Current use of medications (e.g., anticoagulants such as heparin or warfarin) that in the investigator's opinion may compromise patient safety or trial objectives.
8. The patient has a known hypersensitivity to trypsin, compound sodium lactate for irrigation solution (Hartmann's solution), povidone-iodine, chlorhexidine, and/or lidocaine-containing anesthetics -

Primary outcomes:
measure: Repigmentation 0%,1-25%, 26-50%, 51-79%, 80-99%, and 100%)
timeFrame: 24 weeks post-treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Affiliated Dermatology
state: Arizona
city: Irvine
country: United States
facility: University of California, Irvine
state: California
city: San Diego
country: United States
facility: West Dermatology Research Center
state: California
city: Sunnyvale
country: United States
facility: Sutter Health
state: California
city: Thousand Oaks
country: United States
facility: California Dermatology Institute
state: California
city: Castle Rock
country: United States
facility: Clarity Dermatology
state: Colorado
city: Boynton Beach
country: United States
facility: Siperstein Dermatology Group
state: Florida
city: Hollywood
country: United States
facility: Skin Care Research, LLC
state: Florida
city: Chevy Chase
country: United States
facility: Dermatologic Surgery Center of Washington
state: Maryland
city: Hunt Valley
country: United States
facility: Maryland Laser, Skin & Vein Institute
state: Maryland
city: Worcester
country: United States
facility: University Of Massachusetts
state: Massachusetts
city: Canton
country: United States
facility: Hamzavi Dermatology
state: Michigan
city: Detroit
country: United States
facility: Henry Ford Health
state: Michigan
city: Warren
country: United States
facility: Grekin Skin Institute
state: Michigan
city: New York
country: United States
facility: The Dermatology Specialist
state: New York
city: New York
country: United States
facility: Mount Sinai
state: New York
city: Charlotte
country: United States
facility: Dermatology, Laser and Vein Specialists of the Carolinas
state: North Carolina
Study officials:
References: